SMYD3抗体—艾普蒂

SMYD3 (SET and MYND domain-containing protein 3) is a lysine methyltransferase that plays a critical role in epigenetic regulation by catalyzing the methylation of histone H3 lysine 4 (H3K4) and non-histone targets. It has been implicated in transcriptional activation, cell cycle progression, and oncogenesis. Overexpression of SMYD3 is associated with various cancers, including liver, breast, pancreatic, and colorectal cancers, where it promotes tumor proliferation, metastasis, and drug resistance by modulating cancer-related pathways such as Wnt/β-catenin and MAPK/ERK. SMYD3 antibodies are essential tools for detecting and quantifying SMYD3 expression in research and diagnostic contexts. These antibodies, often generated in rabbits or mice using immunogenic peptide sequences, are validated for specificity through techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). They enable the study of SMYD3's subcellular localization, interaction partners, and dysregulation in diseases. Recent studies also explore SMYD3 as a potential therapeutic target, with antibodies aiding in preclinical evaluations of inhibitors. Reliable SMYD3 antibodies are crucial for advancing cancer biology research and developing targeted epigenetic therapies.